Create Medicines (formerly Myeloid Therapeutics) announced a strategic rebrand and expanded its in‑vivo mRNA‑LNP immune programming platform beyond myeloid cells to include T and NK cell programming, aiming to deliver scalable, redosable cell therapies without ex vivo manufacturing. The company emphasized direct in‑patient programming to reduce manufacturing complexity and accelerate access to CAR‑like therapies. Liberate Bio emerged from stealth with $31 million seed funding from Khosla Ventures to develop LNPs for in‑vivo cell therapies, joining a growing cohort pursuing systemic delivery to reprogram immune cells. Both companies highlight strong investor and strategic interest in LNP‑enabled, in‑vivo approaches to cellular immunotherapy. The developments illustrate a shift toward platform approaches that decouple cell therapy potency from complex manufacturing, raising questions on durability, targeting specificity, and regulatory pathways for in‑body gene programming.